Our programs
How it works
Written by Dr. Thomas Kingsley Brown, PhD, Data Science & Research Advisor to Beond.
What ibogaine is, what the research shows, and what it doesn’t, written for you, your doctor, and anyone helping you decide.
If you’re considering ibogaine, or evaluating it for someone you love, this page explains how ibogaine has been used medically, what studies show, and what its effects, side effects, and risks are. For clinicians and researchers, it also offers an orientation to the academic literature.
Beond is a medically supervised ibogaine clinic in Cancún, Mexico, for people living with PTSD, depression, anxiety, and chemical dependency, and for personal growth. Physicians screen every guest, monitor treatment continuously, and work alongside coaches who support guests before and after treatment.
The honest answer: researchers don’t fully know yet. They’re studying whether ibogaine’s intense experience, and the brain changes that may follow, affect habitual patterns of craving and thought. Some people report lasting change, but this hasn’t been confirmed in controlled trials, and results vary.
In animal studies at UCSF, Dorit Ron, Patricia Janak, and colleagues found that ibogaine reduced alcohol drinking and raised GDNF in a midbrain reward region; blocking GDNF weakened the effect (R1). GDNF supports the survival and function of certain neurons. Whether the same happens in people, and whether it explains any benefit, is unknown.
The most developed evidence is for opioid dependence and for PTSD in veterans with mild brain injury. Most studies are small, and larger trials are underway.
Observational studies report less withdrawal and craving after treatment, and one 12-month follow-up reported reduced use in some participants (R7 to R9). In a retrospective study of 75 people in Brazil, 61% were abstinent when surveyed, with median abstinence of about 5.5 months after one treatment and 8.4 months after several (R10). None had a control group.
A small clinical study and a retrospective study report reduced cocaine craving or longer abstinence (R10, R14). Evidence is limited.
A Stanford Medicine study published in 2024, led by Dr. Nolan Williams and colleagues, followed 30 male Special Operations veterans with mostly mild traumatic brain injury who chose treatment with ibogaine and magnesium. They reported improvements in disability, PTSD, depression, and anxiety one month later, with no unexpected or serious adverse events (R11). A 12-month follow-up preprint reported that most improvements held (R17). It was a prospective observational study with no control group. Depression and anxiety occurred alongside PTSD and brain injury in this group, so those results shouldn't be assumed to apply to depression or anxiety on their own.
At one month, average WHO Disability Assessment Schedule 2.0 scores fell from 30.2 to 5.1, clinician-rated effect sizes exceeded 2.0, response rates were at least 93%, and remission rates at least 83%. Formal testing showed improvements in processing speed, executive function, concentration, and memory. No serious adverse or cardiac events were reported; participants reported effects including headache and nausea. A separate MRI analysis of 22 of the 30 participants reported increased cortical thickness in 11 brain regions and a predicted brain age about 1.3 years lower at one month (R31).
There was no control group or placebo; participants received ibogaine with magnesium and other treatments, so ibogaine’s own effect can’t be isolated; follow-up for the main outcomes ended at one month; and the authors say a randomized controlled trial is needed to know whether the MRI changes come from the drug, expectation, the setting, or a combination. They call for replication, especially in people with moderate or severe brain injury.
A 2024 review reported reductions in opioid craving of up to about 50% across open-label and randomized trials, with effects reported up to 24 weeks after a single treatment. It notes that only one double-blind, placebo-controlled randomized trial of ibogaine has been published and that larger trials are needed. Its lead author also led the Stanford study, so the two are not independent sources.
Ibogaine’s main risks are cardiac: it can lengthen the QT interval, slow the heart, and, rarely, cause fatal rhythm problems.
In a small Dutch study, a single dose caused reversible QTc prolongation (about 100 ms on average at the maximum; half of participants exceeded 500 ms) (R5). A review of 19 deaths found that pre-existing conditions (mainly heart disease) or other substances contributed in most cases.
A 2026 preprint of 19,071 treatments at 11 clinics that follow published guidelines found six deaths within 72 hours, all in people treated for opioid dependence, and none among 8,689 people treated for other conditions (R16). Ibogaine’s active metabolite stays in the body for a day or more, so we keep monitoring and repeat an ECG within 24 hours. Certain heart conditions, alcohol or benzodiazepine withdrawal, and substances that affect the CYP2D6 enzyme raise risk.
Ibogaine is not approved by the FDA for any indication and has been a Schedule I controlled substance in the United States since 1970. It can be given legally in a small number of other countries, including Mexico, where it is given in regulated medical settings.
Government-funded research is expanding. Texas is funding its own two-year research program at up to $100 million after being unable to secure a pharmaceutical partner for an earlier, smaller grant program (R12). An April 2026 federal executive order directed additional support for psychedelic research, though it doesn’t change ibogaine’s Schedule I status, and ibogaine doesn’t currently qualify for the order’s priority-voucher provision (R13). No ibogaine product has completed Phase 3 trials or been submitted for FDA approval.
Talk with our team. A physician will review your history and tell you honestly whether what’s known fits your situation.